glp 1 agonist crohn's disease ADJUNCTIVE GLP-1 RECEPTOR AGONISTS IN DISEASE: REDUCED STEROID DEPENDENCE AND HOSPITALIZATIONS IN A REAL-WORLD MULTI-NETWORK COHORT Efficacy and Safety of GLP-1

In the combination therapy pilot (GHK-Cu + PDRN, n = 30, 12 weeks), participants reported a mean increase in hair length of 0.8 mm and a 20% increase in follicular width as determined by trichoscopy

These differences are not merely technical

Selected scientific references BPC-157 and VEGFR2 signaling in experimental models (PMID 27847966) Thymosin beta-4 and experimental wound models (PMID 12581423) Research-use notice: Supplied exclusively for laboratory research and analytical use

2016 Jun;12(3):325-37

doi: 10.1016/j.dsx.2018.03.002 94 OrskovCWettergrenAHolstJJ

Although a huge number of experimental and preclinical investigations have provided encouraging results, clinical trials must be performed and completed to definitely evaluate the usefulness and risks of targeting IGF-1R as an option in cancer treatment of humans